Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 4
2008 5
2009 3
2010 3
2011 6
2012 6
2013 7
2014 6
2015 8
2016 18
2017 22
2018 20
2019 17
2020 20
2021 30
2022 29
2023 21
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Pimavanserin in Dementia-Related Psychosis.
Tariot PN, Cummings JL, Soto-Martin ME, Ballard C, Erten-Lyons D, Sultzer DL, Devanand DP, Weintraub D, McEvoy B, Youakim JM, Stankovic S, Foff EP. Tariot PN, et al. N Engl J Med. 2021 Jul 22;385(4):309-319. doi: 10.1056/NEJMoa2034634. N Engl J Med. 2021. PMID: 34289275 Clinical Trial.
The effects of the oral 5-HT(2A) inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are not clear. ...During the double-blind phase, adverse events occurred in 43 of 105 patients (41.0%) in the pimavanserin group and in 41 …
The effects of the oral 5-HT(2A) inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are n …
The psychosis spectrum in Parkinson disease.
Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D. Ffytche DH, et al. Nat Rev Neurol. 2017 Feb;13(2):81-95. doi: 10.1038/nrneurol.2016.200. Epub 2017 Jan 20. Nat Rev Neurol. 2017. PMID: 28106066 Free PMC article. Review.
In 2007, the clinical and research profile of illusions, hallucinations, delusions and related symptoms in Parkinson disease (PD) was raised with the publication of a consensus definition of PD psychosis. ...In addition, we highlight novel risk factors - for example …
In 2007, the clinical and research profile of illusions, hallucinations, delusions and related symptoms in Parkinson disease (PD) was …
Pimavanserin.
Hunter NS, Anderson KC, Cox A. Hunter NS, et al. Drugs Today (Barc). 2015 Nov;51(11):645-52. doi: 10.1358/dot.2015.51.11.2404001. Drugs Today (Barc). 2015. PMID: 26744739 Review.
Pimavanserin (ACP-103) is a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor intended to treat patients with Parkinson's disease psychosis (PDP). ...Such promising outcomes warrant a review of the available literature regarding pimavanserin …
Pimavanserin (ACP-103) is a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor intended to treat patients with …
New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression.
Orzelska-Górka J, Mikulska J, Wiszniewska A, Biała G. Orzelska-Górka J, et al. Int J Mol Sci. 2022 Sep 13;23(18):10624. doi: 10.3390/ijms231810624. Int J Mol Sci. 2022. PMID: 36142523 Free PMC article. Review.
The purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, pimavanserin) in treatment of schizophrenia and depression. We have …
The purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, …
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
Bugarski-Kirola D, Arango C, Fava M, Nasrallah H, Liu IY, Abbs B, Stankovic S. Bugarski-Kirola D, et al. Lancet Psychiatry. 2022 Jan;9(1):46-58. doi: 10.1016/S2215-0366(21)00386-2. Epub 2021 Nov 30. Lancet Psychiatry. 2022. PMID: 34861170 Clinical Trial.
Both pimavanserin and placebo were administered orally once daily as two individual tablets (pimavanserin tablets were either 10 mg or 17 mg). ...FINDINGS: Between Nov 4, 2016, and April 16, 2019, we randomly assigned 403 patients to pimavanserin (n=201; 131 …
Both pimavanserin and placebo were administered orally once daily as two individual tablets (pimavanserin tablets were either …
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Cummings J, et al. Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1. Lancet. 2014. PMID: 24183563 Clinical Trial.
FINDINGS: Between Aug 11, 2010, and Aug 29, 2012, we randomly allocated 199 patients to treatment groups. For 90 recipients of placebo and 95 recipients of pimavanserin included in the primary analysis, pimavanserin was associated with a -5.79 decrease in SAPS-PD …
FINDINGS: Between Aug 11, 2010, and Aug 29, 2012, we randomly allocated 199 patients to treatment groups. For 90 recipients of placebo and 9 …
Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval.
Schubmehl S, Sussman J. Schubmehl S, et al. Am J Geriatr Psychiatry. 2018 Oct;26(10):1007-1011. doi: 10.1016/j.jagp.2018.06.001. Epub 2018 Jun 14. Am J Geriatr Psychiatry. 2018. PMID: 30072306
In 2016, pimavanserin, a 5-hydroxytryptamine 2A inverse agonist, became the first U.S. ...Furthermore, this article reviews analyses completed by an FDA statistical reviewer that call into question whether pimavanserin demonstrated a clinically significant differenc …
In 2016, pimavanserin, a 5-hydroxytryptamine 2A inverse agonist, became the first U.S. ...Furthermore, this article reviews analyses …
New Antipsychotic Medications in the Last Decade.
Pahwa M, Sleem A, Elsayed OH, Good ME, El-Mallakh RS. Pahwa M, et al. Curr Psychiatry Rep. 2021 Nov 29;23(12):87. doi: 10.1007/s11920-021-01298-w. Curr Psychiatry Rep. 2021. PMID: 34843030 Review.
RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, and pimavanserin; introduction of new delivery methods: subcutaneous long-acting risperidone, aripiprazole lauroxil, transdermal ase …
RECENT FINDINGS: We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, …
Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Cummings J, Ballard C, Tariot P, Owen R, Foff E, Youakim J, Norton J, Stankovic S. Cummings J, et al. J Prev Alzheimers Dis. 2018;5(4):253-258. doi: 10.14283/jpad.2018.29. J Prev Alzheimers Dis. 2018. PMID: 30298184 Free PMC article. Review.
Patients in the pimavanserin group experienced a significant (p=0.001) improvement in Scale for the Assessment of Positive Symptoms - Parkinson's disease (SAPS-PD) scores vs. placebo. In a subgroup analysis of patients with cognitive impairment (MMSE score 21 but 24 …
Patients in the pimavanserin group experienced a significant (p=0.001) improvement in Scale for the Assessment of Positive Symptoms - …
Pimavanserin in Parkinson's Disease-induced Psychosis: A Literature Review.
Patel RS, Bhela J, Tahir M, Pisati SR, Hossain S. Patel RS, et al. Cureus. 2019 Jul 28;11(7):e5257. doi: 10.7759/cureus.5257. Cureus. 2019. PMID: 31572642 Free PMC article. Review.
Pimavanserin was approved for treating Parkinson's disease (PD) psychosis, based upon 21 completed studies. This review article is to understand PD psychosis and assess the efficacy and safety of pimavanserin. ...
Pimavanserin was approved for treating Parkinson's disease (PD) psychosis, based upon 21 completed studies. This review articl …
213 results